Cochrane · systematic review · CD006923

Regular treatment with formoterol for chronic asthma: serious adverse events

Cates, CJ, Cates, MJ · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library

Airways2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 50%High 2 · 33.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Summary of findings ‐ SAE all ages

Population: patients with chronic asthma
2 questions
OutcomeEffectEvidenceStatus / GRADE
SAEs ‐ formoterol versus placebo (
OR 1.57 [1.05, 2.37]19 studies · 6646 participantsHigh
SAEs ‐ formoterol versus salbutamol (
OR 0.72 [0.37, 1.43]9 studies · 2119 participantsModerate

Summary of findings ‐ mortality (all‐cause)

Population: patients with chronic asthma
2 questions
OutcomeEffectEvidenceStatus / GRADE
Mortality (all‐cause) ‐ formoterol versus placebo (
OR 1.52 [0.24, 9.71]14 studies · 5463 participantsModerate
Mortality (all‐cause) ‐ formoterol versus salbutamol (
OR 0.5 [0.03, 8.05]6 studies · 1418 participantsModerate

Summary of findings ‐ SAE children

Population: patients with chronic asthma (children)
2 questions
OutcomeEffectEvidenceStatus / GRADE
SAEs ‐ formoterol versus placebo (
OR 2.82 [1.16, 6.83]5 studies · 1335 participantsHigh
SAEs ‐ formoterol versus salbutamol
no estimate extractedNRNo studies